SABS
SAB Biotherapeutics Inc
NASDAQ: SABS · HEALTHCARE · BIOTECHNOLOGY
$3.74
+7.47% today
Updated 2026-04-30
Market cap
$248.07M
P/E ratio
—
P/S ratio
2.96x
EPS (TTM)
$-0.79
Dividend yield
—
52W range
$2 – $5
Volume
0.6M
SAB Biotherapeutics Inc (SABS) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $3.44M | $55.24M | $60.88M | $23.90M | $2.24M | $1.32M | $0.00 |
| Revenue growth (YoY) | — | +1504.8% | +10.2% | -60.7% | -90.6% | -40.9% | -100.0% |
| Cost of revenue | — | — | $1.65M | $3.29M | $3.75M | $4.79M | $3.08M |
| Gross profit | $3.44M | $55.24M | $59.22M | $20.61M | $-1.51M | $-3.47M | $-3.08M |
| Gross margin | 100.0% | 100.0% | 97.3% | 86.2% | -67.3% | -262.4% | — |
| R&D | $8.02M | $27.91M | $57.18M | $36.44M | $16.52M | $30.16M | $34.35M |
| SG&A | $4.10M | $6.77M | $17.09M | $16.38M | $23.80M | $13.98M | $14.60M |
| Operating income | $-8.67M | $20.56M | $-13.39M | $-28.92M | $-38.08M | $-42.91M | $-48.95M |
| Operating margin | -252.0% | 37.2% | -22.0% | -121.0% | -1700.5% | -3244.9% | — |
| EBITDA | $-8.23M | $21.14M | $-15.20M | $-15.12M | $-38.13M | $-28.99M | $16.60M |
| EBITDA margin | -239.2% | 38.3% | -25.0% | -63.3% | -1703.1% | -2192.5% | — |
| EBIT | $-8.56M | $20.59M | $-16.85M | $-18.41M | $-41.88M | $-33.79M | $13.51M |
| Interest expense | $428476.00 | $469151.00 | $294459.00 | $301584.00 | $315284.00 | $318401.00 | $240664.00 |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-8.99M | $20.12M | $-17.14M | $-18.74M | $-42.19M | $-34.11M | $13.27M |
| Net income growth (YoY) | — | +323.9% | -185.2% | -9.3% | -125.1% | +19.2% | +138.9% |
| Profit margin | -261.1% | 36.4% | -28.2% | -78.4% | -1884.5% | -2579.0% | — |